Alifedrine

In this article we will address the topic of Alifedrine, which has been the subject of interest and debate in various areas. Alifedrine has captured the attention of experts and the general public due to its relevance and impact in today's society. Throughout history, Alifedrine has played a fundamental role in different aspects, whether in the social, cultural, technological, political, economic, among others. In this article, we will explore the various dimensions and perspectives related to Alifedrine, with the aim of providing a comprehensive and enriching vision on this topic.

Alifedrine
Clinical data
Other namesD-13625
Routes of
administration		Oral, intravenous[1][2]
Drug classβ-Adrenergic receptor partial agonist; Sympathomimetic
Identifiers
  • 1-cyclohexyl-3-amino]propan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H27NO2
Molar mass289.419 g·mol−1
3D model (JSmol)
  • C((C1=CC=CC=C1)O)NCCC(=O)C2CCCCC2
  • InChI=1S/C18H27NO2/c1-14(18(21)16-10-6-3-7-11-16)19-13-12-17(20)15-8-4-2-5-9-15/h3,6-7,10-11,14-15,18-19,21H,2,4-5,8-9,12-13H2,1H3/t14-,18-/m0/s1
  • Key:UEELVIXXTBPOCF-KSSFIOAISA-N

Alifedrine (INNTooltip International Nonproprietary Name; developmental code name D-13625) is a drug described as a sympathomimetic and cardiotonic or positive inotropic agent which was never marketed.[3][4][5][6] It is a β-adrenergic receptor partial agonist and was studied in the treatment of heart failure.[4][1][2][7] The drug is taken by mouth or intravenously.[1][2] It is a β-hydroxylated substituted amphetamine derivative.[8]

See also

References

  1. ^ a b c Wan SK, Hoff W, Evans TR (1988). "Haemodynamic effects of intravenous and oral alifedrine in patients with cardiac failure". Current Medical Research and Opinion. 11 (4): 242–253. doi:10.1185/03007998809114243. PMID 3215041.
  2. ^ a b c Anand IS, Hughes LO, Whittington JR, Raftery EB (1989). "Acute haemodynamic effects of different doses of alifedrine in congestive heart failure". European Journal of Clinical Pharmacology. 36 (4): 335–341. doi:10.1007/BF00558291. PMID 2737225.
  3. ^ Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 1-PA373. ISBN 978-1-4757-2085-3. Retrieved 29 August 2024.
  4. ^ a b Morton IK, Hall JM (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 10. ISBN 978-0-7514-0499-9. Retrieved 29 August 2024.
  5. ^ Pharmaceutical Manufacturing Encyclopedia. Volumes 1-4. Elsevier Science. 2013. p. 155. ISBN 978-0-8155-1856-3. Retrieved 2024-08-29.
  6. ^ Wainwright CL, Parratt JR (March 1988). "Alifedrine, a positive inotropic agent that moderately reduces the severity of ischaemia and reperfusion-induced ventricular arrhythmias". European Journal of Pharmacology. 147 (3): 373–380. doi:10.1016/0014-2999(88)90171-9. PMID 3378563.
  7. ^ Metzenauer P, Dedecke R, Göbel H, Martorana PA, Stroman F, Szelenyi I (July 1989). "Effects of the novel beta-adrenergic partial agonist alifedrine on cardiac performance in dogs with acute ischemic left ventricular failure". Journal of Cardiovascular Pharmacology. 14 (1): 103–108. doi:10.1097/00005344-198907000-00018. PMID 2475700. S2CID 72099344.
  8. ^ "Alifedrine". PubChem. U.S. National Library of Medicine. Retrieved 29 August 2024.
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia